Cytek Biosciences prelim Q4 revenue beats estimates

Reuters01-12

Cytek Biosciences prelim Q4 revenue beats estimates

Overview

Cell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectations
Company's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEA

Outlook

Cytek expects its total revenue for the full year 2025 to be approximately $201 million
Company sees sustainable growth and profitability in flow cytometry market

Result Drivers

SERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increase
ASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growth
EMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$62 mln	$57.30 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45

Press Release: ID:nGNX3Yh35w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602022513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602022513","market":"nz","top_or_hot":-1,"title":"Cytek Biosciences prelim Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cytek Biosciences prelim Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Cell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectations</p></li><li><p>Company's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEA</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cytek expects its total revenue for the full year 2025 to be approximately $201 million</p></li><li><p>Company sees sustainable growth and profitability in flow cytometry market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increase</p></li><li><p>ASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growth</p></li><li><p>EMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$62 mln</p></td><td><p>$57.30 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45</p></li></ul><p>Press Release: <span>ID:nGNX3Yh35w</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytek Biosciences prelim Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytek Biosciences prelim Q4 revenue beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cytek Biosciences prelim Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Cell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectations</p></li><li><p>Company's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEA</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cytek expects its total revenue for the full year 2025 to be approximately $201 million</p></li><li><p>Company sees sustainable growth and profitability in flow cytometry market</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increase</p></li><li><p>ASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growth</p></li><li><p>EMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$62 mln</p></td><td><p>$57.30 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45</p></li></ul><p>Press Release: <span>ID:nGNX3Yh35w</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL1N3YD09V:1","article_id":"2602022513","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602022513","pubTimestamp":1768212606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cytek Biosciences prelim Q4 revenue beats estimatesOverviewCell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectationsCompany's growth driven by services, reagents, and ins","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTKB":"Cytek BioSciences","BK4539":"次新股","BK4121":"生命科学工具和服务"},"translate_title":"Cytek Biosciences prelim第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":0.9},"content_text":"Cytek Biosciences prelim Q4 revenue beats estimatesOverviewCell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectationsCompany's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEAOutlookCytek expects its total revenue for the full year 2025 to be approximately $201 millionCompany sees sustainable growth and profitability in flow cytometry marketResult DriversSERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increaseASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growthEMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$62 mln$57.30 mln (4 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45Press Release: ID:nGNX3Yh35wFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602022513","isCrawlerRequest":true}